Evidence map›Paper›PMID 39014136›Full record

ArticleScientific reports2024

The admission level of CRP during cardiogenic shock is a strong independent risk marker of mortality.

François Roubille, Miloud Cherbi, Eran Kalmanovich, Quentin Delbaere, Eric Bonnefoy-Cudraz, Etienne Puymirat, Guillaume Schurtz, Edouard Gerbaud, Laurent Bonello, Pascal Lim and 3 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Incriminating the inotrope: Dobutamine, eosinophilia, and myocarditis.The journal of allergy and clinical immunology. Global · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

François RoubillePhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France. francois.roubille@gmail.com.
Miloud CherbiIntensive Cardiac Care Unit, Rangueil University Hospital, 31059, Toulouse, France.
Eran KalmanovichCardiac Intensive Care Unit, Division of Cardiology, Shamir Medical Center, Affiliated to Tel Aviv University Faculty of Medicine, Tel Aviv, Israel.
Quentin DelbaerePhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France.
Eric Bonnefoy-CudrazIntensive Cardiac Care Unit, Lyon Brom University Hospital, Lyon, France.
Etienne PuymiratDepartment of Cardiology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, 75015, Paris, France.
Guillaume SchurtzUrgences Et Soins Intensifs de Cardiologie, CHU Lille, University of Lille, Inserm U1167, 59000, Lille, France.
Edouard GerbaudIntensive Cardiac Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut Lévêque, 5 Avenue de Magellan, 33604, Pessac, France.
Laurent BonelloAix-Marseille Université, 13385, Marseille, France.
Pascal LimIntensive Cardiac Care Unit, Cardiology Department, Henri Mondor University Hospital, AP-HP, Créteil, France.
Guillaume LeurentDepartment of Cardiology, CHU Rennes, Inserm, LTSI-UMR 1099, Univ Rennes 1, 35000, Rennes, France.
Camille RoubilleInternal Medicine Department, Montpellier University Hospital, Montpellier, France.
Clément DelmasPhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory processes are involved not only in coronary artery disease but also in heart failure (HF). Cardiogenic shock (CS) and septic shock are classically distinct although intricate relationships are frequent in daily practice. The impact of admission inflammation in patients with CS is largely unknown. FRENSHOCK is a prospective registry including 772 CS patients from 49 centers. One-month and one-year mortalities were analyzed according to the level of C-reactive protein (CRP) at admission, adjusted on independent predictive factors. Within 406 patients included, 72.7% were male, and the mean age was 67.4 y ± 14.7. Four groups were defined, depending on the quartiles of CRP at admission. Q1 with a CRP < 8 mg/L, Q2: CRP was 8-28 mg/L, Q3: CRP was > 28-69 mg/L, and Q4: CRP was > 69 mg/L. The four groups did not differ regarding main baseline characteristics. However, group Q4 received more often antibiotics in 47.5%, norepinephrine in 66.3%, and needed more frequently respiratory support and renal replacement therapy. Whether at 1 month (P

Indexed as

BiomarkersC-Reactive ProteinShock, CardiogenicAgedAged, 80 and overFemaleHumansMaleMiddle AgedPatient AdmissionPrognosisProspective StudiesRegistriesRisk FactorsBiomarkersC-Reactive ProteinCardiogenic shockCRPEpidemiologyInfectionInflammationMortalityPrognosis

Identifiers

PMID39014136
PMCPMC11252392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.